Retrocorneal membrane interception enhanced penetrating canaloplasty for patients with open angle glaucoma secondary to ICE syndrome.


Journal

International ophthalmology
ISSN: 1573-2630
Titre abrégé: Int Ophthalmol
Pays: Netherlands
ID NLM: 7904294

Informations de publication

Date de publication:
26 Sep 2024
Historique:
received: 17 04 2023
accepted: 15 06 2024
medline: 26 9 2024
pubmed: 26 9 2024
entrez: 26 9 2024
Statut: epublish

Résumé

To assess the efficacy and safety of retrocorneal membrane interception (RMI)-enhanced penetrating canaloplasty in glaucoma secondary to iridocorneal endothelial syndrome (GS-ICE) with open angle or small peripheral anterior synechiae (PAS). A series of 13 patients (13 eyes) with GS-ICE and uncontrolled intraocular pressure (IOP) underwent RMI-enhanced penetrating canaloplasty from March 2019 to October 2020. The patients were followed up at one week, 1 month, 3 months, 6 months, and 12 months, postoperatively. The main outcome measure was surgical success, which was defined as an IOP ≤ 18 mmHg or ≤ 21 mmHg, with glaucoma medications (qualified success), or without glaucoma medications (complete success). Secondary outcome measures were IOP, medication usage, and surgical complications. Among the 13 GS-ICE eyes, 12 (92%) achieved qualified success and 10 (77%) achieved complete success at 12 months postoperatively. The mean IOP decreased from 36.41 ± 8.92 mmHg on 3.0 (IQR 0.5) medications before surgery to 17.09 ± 7.71 mmHg (p = 0.0004) on 0.0 (IQR 0.5) medications (p = 0.0004) at 12 months after surgery. Transient hypotony (38%) and hyphema (38%) were the most common complications. RMI-enhanced penetrating canaloplasty appears effective and safe in treating GS-ICE with open angle or small PAS up to one year of follow up.

Identifiants

pubmed: 39325075
doi: 10.1007/s10792-024-03211-9
pii: 10.1007/s10792-024-03211-9
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

395

Subventions

Organisme : the Key Research and Development Projects of Zhejiang Province
ID : 2022C03112
Organisme : the National Key Research and Development Project of China
ID : 2020YFC2008200
Organisme : the Program for Zhejiang Leading Talent of S&T Innovation
ID : 2021R52012
Organisme : the Zhejiang Provincial Program for the Cultivation of Leading Talents in Colleges and Universities
ID : 2020099
Organisme : the Foundation for Scientific Research and Development of Wenzhou Medical University
ID : QTJ13009

Informations de copyright

© 2024. The Author(s), under exclusive licence to Springer Nature B.V.

Références

Shields MB (1979) Progressive essential iris atrophy, Chandler’s syndrome, and the iris nevus (Cogan-Reese) syndrome: a spectrum of disease. Surv Ophthalmol 24:3–20. https://doi.org/10.1016/0039-6257(79)90143-7
doi: 10.1016/0039-6257(79)90143-7 pubmed: 483159
Walkden A, Au L (2018) Iridocorneal endothelial syndrome: clinical perspectives. Clin Ophthalmol 12:657–664. https://doi.org/10.2147/opth.S143132
doi: 10.2147/opth.S143132 pubmed: 29670326 pmcid: 5898599
Silva L, Najafi A, Suwan Y et al (2018) The iridocorneal endothelial syndrome. Surv Ophthalmol 63:665–676. https://doi.org/10.1016/j.survophthal.2018.01.001
doi: 10.1016/j.survophthal.2018.01.001 pubmed: 29331589
Sacchetti M, Mantelli F, Marenco M et al (2015) Diagnosis and management of iridocorneal endothelial syndrome. Biomed Res Int 2015:763093. https://doi.org/10.1155/2015/763093
doi: 10.1155/2015/763093 pubmed: 26451377 pmcid: 4588350
Imamoglu S, Sevim MS, Yildiz HE et al (2017) Surgical outcomes of patients with iridocorneal endothelial syndrome: a case series. Int Ophthalmol 37:607–613. https://doi.org/10.1007/s10792-016-0317-1
doi: 10.1007/s10792-016-0317-1 pubmed: 27495952
Chandran P, Rao HL, Mandal AK et al (2017) Glaucoma associated with iridocorneal endothelial syndrome in 203 Indian subjects. PLoS ONE 12:e0171884. https://doi.org/10.1371/journal.pone.0171884
doi: 10.1371/journal.pone.0171884 pubmed: 28282413 pmcid: 5345787
Lanzl IM, Wilson RP, Dudley D et al (2000) Outcome of trabeculectomy with mitomycin-C in the iridocorneal endothelial syndrome. Ophthalmology 107:295–297. https://doi.org/10.1016/s0161-6420(99)00077-9
doi: 10.1016/s0161-6420(99)00077-9 pubmed: 10690828
Jain VK, Sharma R, Ojha S et al (2016) Trabeculectomy with mitomycin-C in patients with iridocorneal endothelial syndrome: a case series. J Clin Diagn Res 10:05–06. https://doi.org/10.7860/JCDR/2016/16506.7782
doi: 10.7860/JCDR/2016/16506.7782
Chandran P, Rao HL, Mandal AK et al (2016) Outcomes of primary trabeculectomy with mitomycin-C in glaucoma secondary to iridocorneal endothelial syndrome. J Glaucoma 25:e652-656. https://doi.org/10.1097/IJG.0000000000000268
doi: 10.1097/IJG.0000000000000268 pubmed: 25943731
Mao Z, Guo X, Zhong Y et al (2021) Surgical outcomes of Ahmed glaucoma valve implantation in patients with glaucoma secondary to iridocorneal endothelial syndrome. Eye (Lond) 35:608–615. https://doi.org/10.1038/s41433-020-0912-2
doi: 10.1038/s41433-020-0912-2 pubmed: 32367005
Gebremichael BG, Mohamed A, Chaurasia S et al (2020) Outcomes of Ahmed glaucoma drainage implant in eyes with glaucoma secondary to iridocorneal endothelial syndrome. J Glaucoma 29:567–571. https://doi.org/10.1097/ijg.0000000000001504
doi: 10.1097/ijg.0000000000001504 pubmed: 32251072
Colás-Tomás T, López Tizón E (2020) Ex-PRESS mini-shunt implanted in a pregnant patient with iridocorneal endothelial syndrome. Eur J Ophthalmol 30:Np25-np28. https://doi.org/10.1177/1120672118820508
doi: 10.1177/1120672118820508 pubmed: 30618278
Pathak Ray V, Rao DP, Gulati I (2019) Primary implantation of non-valved glaucoma-drainage-device in sulcus in iridocorneal endothelial syndrome. Int J Ophthalmol 12:1809–1811. https://doi.org/10.18240/ijo.2019.11.23
doi: 10.18240/ijo.2019.11.23 pubmed: 31741874 pmcid: 6848870
Bucher F, Dietlein T, Hermann M et al (2013) Retrocorneal membrane formation after Baerveldt shunt implantation for iridocorneal endothelial syndrome. Cornea 32:e161-163. https://doi.org/10.1097/ICO.0b013e31828989cd
doi: 10.1097/ICO.0b013e31828989cd pubmed: 23538633
Deng Y, Zhang S, Ye W et al (2022) Achieving inner aqueous drain in glaucoma secondary to iridocorneal endothelial syndrome: One year results of penetrating canaloplasty. Am J Ophthalmol 243:83–90. https://doi.org/10.1016/j.ajo.2022.07.006
doi: 10.1016/j.ajo.2022.07.006 pubmed: 35870489
Feng B, Tang X, Sun X et al (2013) Analysis on misdiagnosis and missed diagnosis of iridocorneal endothelial syndrome. Zhonghua Yan Ke Za Zhi 49:637–641
pubmed: 24257361
Wu J, Dong X, Ouyang C et al (2021) Comparison of descemet membrane endothelial keratoplasty for iridocorneal endothelial syndrome and fuchs endothelial dystrophy. Am J Ophthalmol 226:76–82. https://doi.org/10.1016/j.ajo.2021.01.029
doi: 10.1016/j.ajo.2021.01.029 pubmed: 33556383
Laganowski HC, Kerr Muir MG, Hitchings RA (1992) Glaucoma and the iridocorneal endothelial syndrome. Arch Ophthalmol 110:346–350. https://doi.org/10.1001/archopht.1992.01080150044025
doi: 10.1001/archopht.1992.01080150044025 pubmed: 1543451
Zhang S, Hu C, Cheng H et al (2022) Efficacy of bleb-independent penetrating canaloplasty in primary angle-closure glaucoma: one-year results. Acta Ophthalmol 100:e213–e220. https://doi.org/10.1111/aos.14869
doi: 10.1111/aos.14869 pubmed: 33880864
Doe EA, Budenz DL, Gedde SJ et al (2001) Long-term surgical outcomes of patients with glaucoma secondary to the iridocorneal endothelial syndrome. Ophthalmology 108:1789–1795. https://doi.org/10.1016/s0161-6420(01)00725-4
doi: 10.1016/s0161-6420(01)00725-4 pubmed: 11581050
Kidd M, Hetherington J, Magee S (1988) Surgical results in iridocorneal endothelial syndrome. Arch Ophthalmol 106:199–201. https://doi.org/10.1001/archopht.1988.01060130209027
doi: 10.1001/archopht.1988.01060130209027 pubmed: 3341974
Kim DK, Aslanides IM, Schmidt CM Jr et al (1999) Long-term outcome of aqueous shunt surgery in ten patients with iridocorneal endothelial syndrome. Ophthalmology 106:1030–1034. https://doi.org/10.1016/S0161-6420(99)00529-1
doi: 10.1016/S0161-6420(99)00529-1 pubmed: 10328409
Lin MM, Morgan WH, Kolomeyer NN et al (2020) XEN gel stent to treat ICE syndrome: 4 cases. J Glaucoma 29:e26. https://doi.org/10.1097/IJG.0000000000001449
doi: 10.1097/IJG.0000000000001449 pubmed: 32229787
Pathak Ray V, Rao DP (2018) Surgical outcomes of a new affordable non-valved glaucoma drainage device and Ahmed glaucoma valve: comparison in the first year. Br J Ophthalmol. https://doi.org/10.1136/bjophthalmol-2017-311716
doi: 10.1136/bjophthalmol-2017-311716 pubmed: 29945893
Campbell DG, Shields MB, Smith TR (1978) The corneal endothelium and the spectrum of essential iris atrophy. Am J Ophthalmol 86:317–324. https://doi.org/10.1016/0002-9394(78)90232-5
doi: 10.1016/0002-9394(78)90232-5 pubmed: 717494
Patel A, Kenyon KR, Hirst LW et al (1983) Clinicopathologic features of Chandler’s syndrome. Surv Ophthalmol 27:327–344. https://doi.org/10.1016/0039-6257(83)90234-5
doi: 10.1016/0039-6257(83)90234-5 pubmed: 6344293
Tsai CS, Ritch R, Straus SE et al (1990) Antibodies to Epstein-Barr virus in iridocorneal endothelial syndrome. Arch Ophthalmol 108:1572–1576. https://doi.org/10.1001/archopht.1990.01070130074034
doi: 10.1001/archopht.1990.01070130074034 pubmed: 2173898
Wilson MC, Shields MB (1989) A comparison of the clinical variations of the iridocorneal endothelial syndrome. Arch Ophthalmol 107:1465–1468. https://doi.org/10.1001/archopht.1989.01070020539035
doi: 10.1001/archopht.1989.01070020539035 pubmed: 2803093
Matlach J, Dhillon C, Hain J et al (2015) Trabeculectomy versus canaloplasty (TVC study) in the treatment of patients with open-angle glaucoma: a prospective randomized clinical trial. Acta Ophthalmol 93:753–761. https://doi.org/10.1111/aos.12722
doi: 10.1111/aos.12722 pubmed: 25847610 pmcid: 6680218
Brusini P (2014) Canaloplasty in open-angle glaucoma surgery: a four-year follow-up. Sci World J 2014:469609. https://doi.org/10.1155/2014/469609
doi: 10.1155/2014/469609

Auteurs

Mengtian Zhou (M)

The Eye Hospital, School of Ophthalmology and Optometry, Wenzhou Medical University, Wenzhou, China.
Glaucoma Research Institute, Wenzhou Medical University, Wenzhou, China.
National Clinical Research Center for Ocular Diseases, Glaucoma Research Institute of Wenzhou Medical University, The Eye Hospital of Wenzhou Medical University, Wenzhou, 325027, Zhejiang, China.

Shuqing Zhu (S)

The Eye Hospital, School of Ophthalmology and Optometry, Wenzhou Medical University, Wenzhou, China.
Glaucoma Research Institute, Wenzhou Medical University, Wenzhou, China.
National Clinical Research Center for Ocular Diseases, Glaucoma Research Institute of Wenzhou Medical University, The Eye Hospital of Wenzhou Medical University, Wenzhou, 325027, Zhejiang, China.

Haoyu Li (H)

The Eye Hospital, School of Ophthalmology and Optometry, Wenzhou Medical University, Wenzhou, China.
Glaucoma Research Institute, Wenzhou Medical University, Wenzhou, China.
National Clinical Research Center for Ocular Diseases, Glaucoma Research Institute of Wenzhou Medical University, The Eye Hospital of Wenzhou Medical University, Wenzhou, 325027, Zhejiang, China.

Wenqing Ye (W)

The Eye Hospital, School of Ophthalmology and Optometry, Wenzhou Medical University, Wenzhou, China.
Glaucoma Research Institute, Wenzhou Medical University, Wenzhou, China.
National Clinical Research Center for Ocular Diseases, Glaucoma Research Institute of Wenzhou Medical University, The Eye Hospital of Wenzhou Medical University, Wenzhou, 325027, Zhejiang, China.

Shuxia Xu (S)

The Eye Hospital, School of Ophthalmology and Optometry, Wenzhou Medical University, Wenzhou, China.
Glaucoma Research Institute, Wenzhou Medical University, Wenzhou, China.
National Clinical Research Center for Ocular Diseases, Glaucoma Research Institute of Wenzhou Medical University, The Eye Hospital of Wenzhou Medical University, Wenzhou, 325027, Zhejiang, China.

Haishuang Lin (H)

The Eye Hospital, School of Ophthalmology and Optometry, Wenzhou Medical University, Wenzhou, China.
Glaucoma Research Institute, Wenzhou Medical University, Wenzhou, China.
National Clinical Research Center for Ocular Diseases, Glaucoma Research Institute of Wenzhou Medical University, The Eye Hospital of Wenzhou Medical University, Wenzhou, 325027, Zhejiang, China.

Jinxin Li (J)

The Eye Hospital, School of Ophthalmology and Optometry, Wenzhou Medical University, Wenzhou, China.
Glaucoma Research Institute, Wenzhou Medical University, Wenzhou, China.
National Clinical Research Center for Ocular Diseases, Glaucoma Research Institute of Wenzhou Medical University, The Eye Hospital of Wenzhou Medical University, Wenzhou, 325027, Zhejiang, China.

Jinyuan Chen (J)

Department of Ophthalmology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China.

Shaodan Zhang (S)

The Eye Hospital, School of Ophthalmology and Optometry, Wenzhou Medical University, Wenzhou, China.
Glaucoma Research Institute, Wenzhou Medical University, Wenzhou, China.
National Clinical Research Center for Ocular Diseases, Glaucoma Research Institute of Wenzhou Medical University, The Eye Hospital of Wenzhou Medical University, Wenzhou, 325027, Zhejiang, China.

Clement C Tham (CC)

Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Sha Tin, Hong Kong SAR, China.

Ningli Wang (N)

Beijing Tongren Eye Center, Beijing Tongren Hospital, Beijing Key Laboratory of Ophthalmology and Visual Sciences, Beijing Institute of Ophthalmology, Capital Medical University, No. 1 Dongjiaominxiang Street, Beijing, 100730, Dongcheng District, China. wningli@vip.163.com.
Beijing Institute of Ophthalmology, Beijing, China. wningli@vip.163.com.

Yuanbo Liang (Y)

The Eye Hospital, School of Ophthalmology and Optometry, Wenzhou Medical University, Wenzhou, China. yuanboliang@126.com.
Glaucoma Research Institute, Wenzhou Medical University, Wenzhou, China. yuanboliang@126.com.
National Clinical Research Center for Ocular Diseases, Glaucoma Research Institute of Wenzhou Medical University, The Eye Hospital of Wenzhou Medical University, Wenzhou, 325027, Zhejiang, China. yuanboliang@126.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH